More Than 400 Innovative Medicines in Development For Top Chronic Diseases Affecting Older Americans

WASHINGTON, D.C. (March 20, 2013) – America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditions affecting seniors, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

With the population of Americans over 65 on the rise and life expectancy climbing, chronic diseases remain a principal threat to the health and productivity of older Americans, as well as to rising health care costs. Innovative medicines have led to major advances against many chronic diseases – and the robust discovery pipeline of new medicines portends continued progress for seniors and our health care system.

Medicines in Development for Older Americans - Clinical Trial Backgrounder

The 668 clinical trials listed here include 406 that have not yet started recruiting patients or are just now seeking volunteers to participate and another 262 that are active, but not recruiting new patients. This information is potentially valuable to patients still seeking effective treatments for the top ten chronic diseases affecting seniors. It provides a new therapeutic option to discuss with physicians.

Biologics Research Promises to Bolster Future of Medicine

WASHINGTON, D.C. (March 11, 2013) – America’s biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The report includes biologics in human clinical trials or under review by the U.S. Food and Drug Administration such as:

PhRMA Urges Trans-Pacific Partnership Negotiators to Adopt a Strong Intellectual Property Framework

SINGAPORE (March 4, 2013) –The Pharmaceutical Research and Manufacturers of America (PhRMA) today called on nations participating in the 16th round of Trans-Pacific Partnership (TPP) negotiations to prioritize the protection of intellectual property, citing the critical importance of strong IP to develop innovative treatments for diseases ranging from Alzheimer’s and Parkinson’s to cancer and diabetes.

RA Report: Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis

Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis

Recognizing the Value of Innovation in Rheumatoid Arthritis

PhRMA Statement on Proposal for an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need

WASHINGTON, D.C. (February 28, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific & Regulatory Affairs Sascha Haverfield issued the following statement today regarding the proposal to create a potential new drug approval pathway intended to expedite the development of new medicines for serious or life-threatening conditions that would address an unmet medical need, including medicines for serious or life-threatening infections caused by antibiotic-resistant bacteria:

PhRMA Statement on Time Magazine Article

WASHINGTON, D.C. (February 21, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement:

“Today’s Time Magazine article focuses exclusively on costs, overlooking the tremendous value that innovative medicines deliver to patients and the health care system for only a small fraction of overall health spending. Across the spectrum of diseases, medications have significantly improved quality and length of life.

Washington State Research Institutions Have Conducted More Than 3,600 Clinical Trials of New Medicines Since 1999

 WASHINGTON, D.C. (January 29, 2013) –Working in collaboration with university medical schools, science centers, local hospitals and clinical research centers, America’s biopharmaceutical companies have conducted 3,664 clinical trials of new medicines in Washington over the last 13 years, a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows.

Pages

Subscribe to RSS - Innovation